Castle Biosciences Honored with Top Workplaces Awards
2024年7月11日 - 8:00PM
ビジネスワイヤ(英語)
Castle earns recognition as an Arizona Top
Workplace, a national Healthcare Industry Top Workplace and
receives five Top Workplaces Culture Excellence Awards
Castle Biosciences, Inc. (Nasdaq: CSTL), a company improving
health through innovative tests that guide patient care, today
announced that it has earned multiple awards through the 2024 Top
Workplaces program, including: a third consecutive Arizona Top
Workplaces award from AZ Central, the digital home of The Arizona
Republic newspaper; a second consecutive national Healthcare
Industry Top Workplaces award; and five Top Workplaces Culture
Excellence Awards for Innovation, Work-Life Flexibility,
Compensation & Benefits, Leadership and Purpose &
Values.
“We are incredibly honored to have been named a Top Workplace in
Arizona for the third year in a row in addition to being
twice-recognized as a national Top Workplace in the Healthcare
Industry among so many distinguished companies,” said Derek
Maetzold, president and chief executive officer of Castle
Biosciences. “Receiving multiple, consecutive Top Workplace
designations holds immense significance, as they stem directly from
feedback received from our Castle team members. These achievements
exemplify our steadfast commitment to fostering an exceptional,
people-first workplace culture that inspires our team members and
fuels our shared passion for improving patient care.”
Now in its 17th year, the Top Workplaces program surveys and
celebrates people-first organizations nationally and across 60
regional markets. Top Workplace designations are garnered solely
through anonymous employee feedback gathered through a third-party
survey administered by Energage. The confidential survey uniquely
measures the employee experience and its component themes,
including employees feeling “respected & supported,” “enabled
to grow” and “empowered to execute,” among others. Additionally, it
measures 15 culture drivers that are indicative of successful
organizations, such as alignment, execution and connection.
Earlier this year, Castle earned a national Top Workplaces award
(also for the third consecutive year) and also received five Top
Workplaces Culture Excellence Awards (multiple years running) for
continued excellence in the following areas of its company
culture:
- Innovation (2022, 2023, 2024), for creating a
culture where new ideas are encouraged, which helps employees reach
their full potential and benefits performance.
- Work-Life Flexibility (2023, 2024), for building
a culture that enables employees to meet the demands of their
personal lives while maintaining high performance.
- Compensation & Benefits (2022, 2023, 2024),
for providing packages employees believe are fair for the work
being done and compared to others in the industry.
- Leadership (2022, 2023, 2024), for organizational
leaders who inspire confidence in employees and the company
direction, listening to what matters most to employees and using
that insight in decision making.
- Purpose & Values (2022, 2023, 2024), for
successfully communicating the company mission and integrating
those aspirations into the culture.
“Earning a Top Workplaces award is a badge of honor for
companies, especially because it comes authentically from their
employees,” said Eric Rubino, Energage chief executive officer. “In
today's market, leaders must ensure they’re allowing employees to
have a voice and be heard; that's paramount. Top Workplaces do
this, and it pays dividends.”
About Castle Biosciences
Castle Biosciences (Nasdaq: CSTL) is a leading diagnostics
company improving health through innovative tests that guide
patient care. The Company aims to transform disease management by
keeping people first: patients, clinicians, employees and
investors.
Castle’s current portfolio consists of tests for skin cancers,
Barrett’s esophagus, mental health conditions and uveal melanoma.
Additionally, the Company has active research and development
programs for tests in other diseases with high clinical need,
including its test in development to help guide systemic therapy
selection for patients with moderate-to-severe atopic dermatitis,
psoriasis and related conditions. To learn more, please visit
www.CastleBiosciences.com and connect with us on LinkedIn,
Facebook, X and Instagram.
DecisionDx-Melanoma, DecisionDx-CMSeq, DecisionDx-SCC, MyPath
Melanoma, DiffDx-Melanoma, TissueCypher, IDgenetix, DecisionDx-UM,
DecisionDx-PRAME and DecisionDx-UMSeq are trademarks of Castle
Biosciences, Inc.
About Energage
Making the world a better place to work together.™
Energage is a purpose-driven company that helps organizations
turn employee feedback into useful business intelligence and
credible employer recognition through Top Workplaces. Built on 18
years of culture research and the results from 27 million employees
surveyed across more than 70,000 organizations, Energage delivers
the most accurate competitive benchmark available. With access to a
unique combination of patented analytic tools and expert guidance,
Energage customers lead the competition with an engaged workforce
and an opportunity to gain recognition for their people-first
approach to culture. For more information or to nominate your
organization, visit energage.com or topworkplaces.com.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20240711288149/en/
Investor Contact: Camilla Zuckero
czuckero@castlebiosciences.com
Media Contact: Allison Marshall
amarshall@castlebiosciences.com
Castle Biosciences (NASDAQ:CSTL)
過去 株価チャート
から 7 2024 まで 7 2024
Castle Biosciences (NASDAQ:CSTL)
過去 株価チャート
から 7 2023 まで 7 2024